达维塔保健今日盘前股价大幅上涨13.54%，引起了市场的广泛关注。
消息面上，公司公布了强劲的第四季度财报及2026年业绩展望。其第四季度调整后每股收益为3.40美元，营收为36.2亿美元，均超出市场预期。同时，公司给出的2026年调整后每股利润指引区间为13.6美元至15美元，显著高于分析师普遍预期的12.65美元。稳定的透析服务需求、较高的报销率以及运营状况的改善，共同推动了业绩向好。
此外，公司宣布将与临终关怀服务提供商Elara合作，开发一种专门针对肾脏的家庭护理模式，旨在减少可预防的住院治疗并改善患者治疗效果。这一战略合作进一步增强了市场对公司未来增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.